Novo Nordisk ​said on ‌Monday that in a ​late-stage trial, ​40.4% of children ⁠aged 6 ​to under ​12 treated with semaglutide, the ​active ingredient ​in its blockbuster ‌weight-loss ⁠drug Wegovy, were no longer classified ​as ​having ⁠obesity after 68 ​weeks, ​assuming ⁠full adherence to the ⁠treatment.